Kan Gong

2.8k total citations
116 papers, 1.9k citations indexed

About

Kan Gong is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kan Gong has authored 116 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Molecular Biology, 57 papers in Pulmonary and Respiratory Medicine and 56 papers in Cancer Research. Recurrent topics in Kan Gong's work include Cancer, Hypoxia, and Metabolism (43 papers), Renal cell carcinoma treatment (36 papers) and Renal and related cancers (24 papers). Kan Gong is often cited by papers focused on Cancer, Hypoxia, and Metabolism (43 papers), Renal cell carcinoma treatment (36 papers) and Renal and related cancers (24 papers). Kan Gong collaborates with scholars based in China, United States and United Kingdom. Kan Gong's co-authors include Jingcheng Zhou, Kaifang Ma, Kenan Zhang, Haibiao Xie, Yanqing Gong, Lin Cai, Baoan Hong, Wuping Yang, Xianghui Ning and Jiangyi Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Molecular Cell.

In The Last Decade

Kan Gong

108 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kan Gong China 24 1.1k 747 631 339 315 116 1.9k
Jodi K. Maranchie United States 21 1.1k 1.1× 944 1.3× 704 1.1× 347 1.0× 356 1.1× 82 2.1k
Silvia Saviozzi Italy 22 1.7k 1.6× 770 1.0× 694 1.1× 731 2.2× 391 1.2× 36 2.7k
Eri Arai Japan 30 1.5k 1.4× 597 0.8× 446 0.7× 427 1.3× 326 1.0× 78 2.2k
Christina Selinger Australia 22 864 0.8× 660 0.9× 726 1.2× 928 2.7× 343 1.1× 50 2.1k
Iacopo Petrini Italy 27 884 0.8× 688 0.9× 723 1.1× 1.0k 3.0× 220 0.7× 91 2.5k
Kazuki Yamanaka Japan 23 756 0.7× 335 0.4× 512 0.8× 487 1.4× 259 0.8× 65 1.6k
Marco Lo Iacono Italy 21 1.3k 1.2× 729 1.0× 678 1.1× 594 1.8× 193 0.6× 46 2.2k
Josep Domingo‐Domenech United States 19 1.2k 1.1× 599 0.8× 593 0.9× 885 2.6× 402 1.3× 46 2.1k
Hsuan-Ying Huang Taiwan 30 1.2k 1.1× 434 0.6× 822 1.3× 700 2.1× 429 1.4× 55 2.4k
Takashi Karashima Japan 24 1.1k 1.0× 547 0.7× 790 1.3× 770 2.3× 558 1.8× 119 2.3k

Countries citing papers authored by Kan Gong

Since Specialization
Citations

This map shows the geographic impact of Kan Gong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kan Gong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kan Gong more than expected).

Fields of papers citing papers by Kan Gong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kan Gong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kan Gong. The network helps show where Kan Gong may publish in the future.

Co-authorship network of co-authors of Kan Gong

This figure shows the co-authorship network connecting the top 25 collaborators of Kan Gong. A scholar is included among the top collaborators of Kan Gong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kan Gong. Kan Gong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Qiu, Jianhui, Jingcheng Zhou, Lin Cai, et al.. (2025). Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study.. Journal of Clinical Oncology. 43(5_suppl). 534–534. 3 indexed citations
3.
4.
Zhang, Zedan, Yi Wang, Wuping Yang, et al.. (2024). Metabolomic landscape of renal cell carcinoma in von Hippel-Lindau syndrome in a Chinese cohort. iScience. 27(7). 110357–110357.
5.
6.
Xu, Yawei, Kenan Zhang, Yizhou Wang, et al.. (2023). Molecular classification and tumor microenvironment characteristics in pheochromocytomas. eLife. 12. 8 indexed citations
7.
Yang, Wuping, Zedan Zhang, Lei Li, et al.. (2023). ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation. Cell Death and Disease. 14(3). 212–212. 9 indexed citations
8.
Zhang, Kenan, Wuping Yang, Zedan Zhang, et al.. (2022). A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma. Journal of Oncology. 2022. 1–19. 4 indexed citations
9.
Zhou, Jingcheng & Kan Gong. (2022). Belzutifan: a novel therapy for von Hippel–Lindau disease. Nature Reviews Nephrology. 18(4). 205–206. 16 indexed citations
10.
Zhang, Zedan, Wuping Yang, Yawei Xu, et al.. (2022). Downregulation of FXYD2 Is Associated with Poor Prognosis and Increased Regulatory T Cell Infiltration in Clear Cell Renal Cell Carcinoma. Journal of Immunology Research. 2022. 1–19. 8 indexed citations
11.
Zhang, Kenan, Wuping Yang, Kaifang Ma, et al.. (2022). Genotype–phenotype correlations and clinical outcomes of patients with von Hippel-Lindau disease with large deletions. Journal of Medical Genetics. 60(5). 477–483.
12.
Xu, Yawei, Lei Li, Wuping Yang, et al.. (2021). Association between vasectomy and risk of prostate cancer: a meta-analysis. Prostate Cancer and Prostatic Diseases. 24(4). 962–975. 4 indexed citations
13.
Zhang, Kenan, Wuping Yang, Kaifang Ma, et al.. (2021). Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients. Journal of Medical Genetics. 59(10). 951–956. 5 indexed citations
14.
Xie, Haibiao, Kaifang Ma, Kenan Zhang, et al.. (2021). Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway. Cell Death and Disease. 12(1). 1–1. 123 indexed citations
15.
Yang, Fan, et al.. (2020). Stereotactic radiosurgery for central nervous system hemangioblastoma in von Hippel-Lindau disease: A systematic review and meta-analysis. Clinical Neurology and Neurosurgery. 195. 105912–105912. 11 indexed citations
16.
Xie, Haibiao, Kaifang Ma, Baoan Hong, et al.. (2020). Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study. Journal of Medical Genetics. 57(11). 744–751. 5 indexed citations
17.
Yang, Wuping, Lei Li, Kenan Zhang, et al.. (2020). CLDN10 Associated with Immune Infiltration is a Novel Prognostic Biomarker for Clear Cell Renal Cell Carcinoma. Epigenomics. 13(1). 31–45. 15 indexed citations
18.
Hu, Lianxin, Haibiao Xie, Xijuan Liu, et al.. (2019). TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss. Cancer Discovery. 10(3). 460–475. 72 indexed citations
19.
Peng, Xiang, Jinchao Chen, Shuanghe Peng, et al.. (2019). Natural history of renal tumours in von Hippel-Lindau disease: a large retrospective study of Chinese patients. Journal of Medical Genetics. 56(6). 380–387. 10 indexed citations
20.
Wang, Jiangyi, Shuanghe Peng, Xianghui Ning, et al.. (2017). Shorter telomere length increases age‐related tumor risks in von Hippel‐Lindau disease patients. Cancer Medicine. 6(9). 2131–2141. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jodi K. Maranchie Breakdown of academic impact, for papers by Silvia Saviozzi Breakdown of academic impact, for papers by Eri Arai Breakdown of academic impact, for papers by Christina Selinger Breakdown of academic impact, for papers by Iacopo Petrini Breakdown of academic impact, for papers by Kazuki Yamanaka Breakdown of academic impact, for papers by Marco Lo Iacono Breakdown of academic impact, for papers by Josep Domingo‐Domenech Breakdown of academic impact, for papers by Hsuan-Ying Huang Breakdown of academic impact, for papers by Takashi Karashima
Rankless by CCL
2026